A detailed history of Federated Hermes, Inc. transactions in Kezar Life Sciences, Inc. stock. As of the latest transaction made, Federated Hermes, Inc. holds 6,226 shares of KZR stock, worth $40,842. This represents 0.0% of its overall portfolio holdings.

Number of Shares
6,226
Previous 8,953 30.46%
Holding current value
$40,842
Previous $5,000 20.0%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$0.53 - $0.77 $1,445 - $2,099
-2,727 Reduced 30.46%
6,226 $4,000
Q2 2024

Aug 08, 2024

SELL
$0.6 - $0.92 $8,717 - $13,366
-14,529 Reduced 61.87%
8,953 $5,000
Q1 2024

May 14, 2024

BUY
$0.8 - $1.05 $2,449 - $3,215
3,062 Added 15.0%
23,482 $21,000
Q4 2023

Jan 31, 2024

SELL
$0.72 - $1.15 $5,175 - $8,266
-7,188 Reduced 26.04%
20,420 $19,000
Q3 2023

Nov 13, 2023

BUY
$1.08 - $2.54 $2,758 - $6,487
2,554 Added 10.19%
27,608 $32,000
Q2 2023

Aug 14, 2023

BUY
$2.31 - $3.06 $53,908 - $71,411
23,337 Added 1359.17%
25,054 $61,000
Q1 2023

May 08, 2023

BUY
$3.13 - $7.31 $5,374 - $12,551
1,717 New
1,717 $5,000
Q2 2022

Aug 15, 2022

SELL
$4.58 - $17.13 $222,867 - $833,562
-48,661 Closed
0 $0
Q1 2022

May 13, 2022

SELL
$12.3 - $18.33 $4,993 - $7,441
-406 Reduced 0.83%
48,661 $809,000
Q4 2021

Feb 14, 2022

BUY
$7.44 - $16.72 $314,957 - $707,807
42,333 Added 628.65%
49,067 $820,000
Q3 2021

Nov 15, 2021

BUY
$4.85 - $9.73 $32,659 - $65,521
6,734 New
6,734 $58,000
Q1 2020

May 13, 2020

SELL
$2.77 - $5.75 $454 - $943
-164 Closed
0 $0
Q3 2019

Nov 14, 2019

BUY
$3.0 - $7.58 $492 - $1,243
164 New
164 $1,000
Q2 2019

Aug 14, 2019

SELL
$7.09 - $21.9 $1,850 - $5,715
-261 Closed
0 $0
Q1 2019

May 10, 2019

BUY
$16.83 - $23.75 $992 - $1,401
59 Added 29.21%
261 $5,000
Q4 2018

Feb 13, 2019

BUY
$20.21 - $32.9 $4,082 - $6,645
202 New
202 $4,000

Others Institutions Holding KZR

About Kezar Life Sciences, Inc.


  • Ticker KZR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,369,504
  • Market Cap $449M
  • Description
  • Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical tria...
More about KZR
Track This Portfolio

Track Federated Hermes, Inc. Portfolio

Follow Federated Hermes, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Federated Hermes, Inc. with notifications on news.